The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) hit a new 52-week low and has $12.31 target or 9.00% below today’s $13.53 share price. The 9 months bearish chart indicates high risk for the $549.98 million company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $12.31 price target is reached, the company will be worth $49.50M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 403,067 shares traded hands. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 49.37% since March 10, 2016 and is downtrending. It has underperformed by 56.89% the S&P500.
Analysts await Intra-Cellular Therapies Inc (NASDAQ:ITCI) to report earnings on November, 3. They expect $-0.81 earnings per share, up 10.99% or $0.10 from last year’s $-0.91 per share. After $-0.71 actual earnings per share reported by Intra-Cellular Therapies Inc for the previous quarter, Wall Street now forecasts 14.08% negative EPS growth.
Intra-Cellular Therapies Inc (NASDAQ:ITCI) Ratings Coverage
Out of 8 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Intra-Cellular Therapies has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Thursday, September 29 by SunTrust. The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) has “Outperform” rating given on Friday, November 6 by RBC Capital Markets. The firm earned “Sell” rating on Friday, August 7 by Zacks. JMP Securities maintained the shares of ITCI in a report on Wednesday, March 9 with “Market Outperform” rating. As per Thursday, September 17, the company rating was maintained by Guggenheim. The stock has “Market Perform” rating given by JMP Securities on Thursday, September 29. Piper Jaffray initiated it with “Overweight” rating and $57 target price in Thursday, June 2 report.
According to Zacks Investment Research, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment increased to 1.71 in Q2 2016. Its up 0.25, from 1.46 in 2016Q1. The ratio improved, as 17 funds sold all Intra-Cellular Therapies Inc shares owned while 28 reduced positions. 23 funds bought stakes while 54 increased positions. They now own 30.01 million shares or 2.84% more from 29.18 million shares in 2016Q1.
Aqr Management Ltd Liability holds 17,162 shares or 0% of its portfolio. Goldman Sachs Gp Incorporated accumulated 0% or 90,350 shares. Bnp Paribas Arbitrage last reported 0% of its portfolio in the stock. Blackrock Ltd Liability Company, a Delaware-based fund reported 1.26M shares. Ameriprise Fincl holds 0% or 8,460 shares in its portfolio. Wall Street Assocs, a California-based fund reported 7,600 shares. The Quebec – Canada-based Fiera Capital has invested 0% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). The Kansas-based Waddell And Reed Financial has invested 0.01% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Ecor1 Capital Ltd holds 3.75% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI) for 244,950 shares. Gsa Capital Partners Ltd Liability Partnership last reported 0.05% of its portfolio in the stock. Wexford Limited Partnership accumulated 0.26% or 37,994 shares. Marshall Wace Llp holds 0% or 9,820 shares in its portfolio. Suffolk Cap Management Lc, a New York-based fund reported 60,754 shares. State Board Of Administration Of Florida Retirement Systems has 0% invested in the company for 14,745 shares. Alliancebernstein Limited Partnership holds 0% or 55,410 shares in its portfolio.
More important recent Intra-Cellular Therapies Inc (NASDAQ:ITCI) news were published by: Fool.com which released: “Why Intra-Cellular Therapies Inc. Is Crashing Today” on September 29, 2016, also Marketwatch.com published article titled: “Intra-Cellular Therapies shares plunge 68% after study results”, Prnewswire.com published: “Intra-Cellular Therapies (ITCI) Alert: Shareholder Rights Law Firm Johnson …” on September 29, 2016. More interesting news about Intra-Cellular Therapies Inc (NASDAQ:ITCI) was released by: Fool.com and their article: “Why Intra-Cellular Therapies Inc Stock Jump 21.4% in April” with publication date: May 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.